Overview

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2 an open-label, multi-center study to determine the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PRT3789 in combination with pembrolizumab in patients with advanced, recurrent or metastatic solid tumors with a SMARCA4 mutation.

Phase:

PHASE2

Details

Lead Sponsor:

Prelude Therapeutics

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

pembrolizumab